CATIE news story
— Long-acting HIV treatment with cabotegravir + rilpivirine is an option for some people.
— International guidelines do not recommend its use during pregnancy due to efficacy concerns.
— Researchers found promising results in pregnancy when oral therapy alone was not an option.
Scientists at the Ottawa Hospital noted that the use of Cabenuva (cabotegravir + rilpivirine) could be helpful during pregnancy in people with HIV. For instance, pregnancy-related nausea can make it difficult to take medicines orally, which would make adherence challenging. They described their experience with the first seven women with HIV who received Cabenuva during pregnancy at their clinic.
Read the full news story here.
Source : CATIE
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.